Jim Krenn

Partner | San Diego
|
(858) 314-7561
I provide strategic advice to help clients achieve their business objectives in major corporate transactions.

Experience

Represented this medical instruments company in its sale to Agilent Technologies (NYSE: A) for $250 million.

Represented this parent company of a regulated electric utility in Alaska in its $170 million sale to Avista (NYSE: AVA).

Represented this medical diagnostic company focused on high-risk medical conditions and diseases in its $90 million sale to bioMérieux (EPA: BIM).

Represented this diversified financial services company in its $53 million private placement and merger with investment banking firm B. Riley & Co.

Represented this private equity-backed developer and manufacturer of laboratory consumables and liquid handling solutions in its sale to Mettler-Toledo (NYSE: MTD) for an undisclosed sum.

Represented this private equity-backed leader in reproductive tissue donor services and stem cell banking in multiple acquisitions.

Represented this provider of natural gas as an alternative fuel for vehicle fleets in its sale for up to $180 million of components of its renewable natural gas business to BP (NYSE: BP).

Represented this biometric identification solutions provider in its $943 million sale to 3M (NYSE: MMM).

Represented this agricultural, construction, and forestry machinery corporation in its announced acquisition of the precision planning unit of Monsanto (NYSE: MON) for an undisclosed sum.

Represented this leading supplier of medical products for the global aesthetic market in its $1.12 billion sale to Johnson & Johnson (NYSE: JNJ).

Represented this developer of smart technology solutions that simplify and accelerate claims handling, repair processes, and pharmacy transactions in its acquisition of Cogent Works for an undisclosed sum.

Represented this managing general agent that utilizes a proprietary, intelligent distribution channel to provide the full continuum of insurance products in its sale to Integrated Specialty Coverages for an undisclosed sum.

Represented this next generation sequencing company in its cross-border sale to an affiliate of Fapon Biotech Inc., a leading reagent supplier based in China, for an undisclosed sum.

Represented this provider of high-power solid-state amplifiers in its $137 million sale to Spacenet, a subsidiary of Gilat Satellite Networks (NASDAQ: GILT).

Represented this developer of cell analysis instrumentation technologies in its $30 million Series E Preferred Stock financing.

Represented this biopharmaceutical company focused on the development of cutting-edge allogeneic immunotherapies for cancer and other diseases in its Series A financing of up to $51 million, and $80 million Series B financing.

Represented this medical diagnostic company focused on high-risk medical conditions and diseases in over $200 million of equity and debt financings.

Represented this private equity-backed leader in reproductive tissue donor services and stem cell banking in multiple equity and debt financings.

Represented this entity as an investor in multiple equity financings, convertible debt financings, and M&A transactions, including transactions involving HemaQuest Pharmaceuticals, LigoCyte Pharmaceuticals, Ambit Biosciences, and Syndax Pharmaceuticals.

Represented this entity and its affiliates as investors in over $100 million in equity financings, debt financings, and secondary transactions, including Coupang and several other prominent e-commerce companies.

Represented this entity as an investor in multiple equity financings, including MobiTV and Brit Media.

Represented this artificial intelligence and machine learning software infrastructure provider, in its $93 million Series B financing.

Represented this biotechnology company developing a new class of precision targeted oncologic drugs in over $470 million of equity financings.

Represented this provider of application-intelligent networking I/O software and hardware platforms in over $200 million of equity and debt financings.

Represented this agriculture technology company focused on seed genetics in over $150 million of equity financings.

Represented this entity as an investor in multiple equity financings, including investments in Hightail and Upthere.